Laurence Turka
2021
In 2021, Laurence Turka earned a total compensation of $2M as Chief Scientific Officer and Head of Research and Translational Medicine at Rubius Therapeutics, a 16% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $189,136 |
|---|---|
| Option Awards | $1,048,858 |
| Salary | $425,850 |
| Stock Awards | $356,108 |
| Other | $11,564 |
| Total | $2,031,516 |
Turka received $1M in option awards, accounting for 52% of the total pay in 2021.
Turka also received $189.1K in non-equity incentive plan, $425.9K in salary, $356.1K in stock awards and $11.6K in other compensation.
Rankings
In 2021, Laurence Turka's compensation ranked 5,996th out of 12,415 executives tracked by ExecPay. In other words, Turka earned more than 51.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,996 out of 12,415 | 52nd |
Division Manufacturing | 2,538 out of 5,501 | 54th |
Major group Chemicals And Allied Products | 1,108 out of 2,371 | 53rd |
Industry group Drugs | 986 out of 2,092 | 53rd |
Industry Biological Products, Except Diagnostic Substances | 240 out of 449 | 47th |
Source: SEC filing on March 30, 2022.
Turka's colleagues
We found four more compensation records of executives who worked with Laurence Turka at Rubius Therapeutics in 2021.